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Abstract 
Background: People living with HIV (PLWH) with a substance use disorder (SUD) tend to receive inadequate medical 
care in part because of a siloed healthcare system in which HIV and substance use services are delivered separately. 
Ideal treatment requires an interdisciplinary, team-based coordinated care approach, but many structural and sys-
temic barriers impede the integration of HIV and SUD services. The current protocol describes the development and 
preliminary evaluation of a care coordination intervention (CCI), consisting of a tablet-based mobile platform for HIV 
and SUD treatment providers, an interagency communication protocol, and a training protocol. We hypothesize that 
HIV and SUD treatment providers will find the CCI to be acceptable, and that after receipt of the CCI, providers will: 
exhibit higher retention in dual care among patients, report increased frequency and quality of communication, and 
report increased rates of relational coordination.
Methods/design: A three phase approach is used to refine and evaluate the CCI. Phase 1 consists of in-depth quali-
tative interviews with 8 key stakeholders as well as clinical audits of participating HIV and SUD treatment agencies. 
Phase 2 contains functionality testing of the mobile platform with frontline HIV and SUD treatment providers, fol-
lowed by refinement of the CCI. Phase 3 consists of a pre-, post-test trial with 30 SUD and 30 HIV treatment providers. 
Data will be collected at the provider, organization, and patient levels. Providers will complete assessments at base-
line, immediately post-training, and at 1-, 3-, and 6-months post-training. Organizational data will be collected at base-
line, 1-, 3-, and 6-months post training, while patient data will be collected at baseline and 6-months post training.
Discussion: This study will develop and evaluate a CCI consisting of a tablet-based mobile platform for treatment 
providers, an interagency communication protocol, and a training protocol as a means of improving the integration 
of care for PLWH who have a SUD. Results have the potential to advance the field by bridging gaps in a fragmented 
healthcare system, and improving treatment efficiency, work flow, and communication among interdisciplinary pro-
viders from different treatment settings.
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Background
Alcohol and illicit drug use remains a substantial problem 
among people living with HIV (PLWH), contributing to 
suboptimal treatment outcomes and increased transmis-
sion of HIV. Over 81% of PLWH report use of an illicit 
drug, and nearly one in four meet diagnostic criteria for a 
substance use disorder (SUD) [1]. Substance use is asso-
ciated with poorer outcomes across the HIV care con-
tinuum including delayed diagnosis and linkage to HIV 
care, decreased adherence to antiretroviral medications, 
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reduced retention in care, increased sexual risk behavior 
leading to inferior clinical outcomes, and increased HIV 
transmission and drug resistance [2]. HIV-infected peo-
ple who use drugs are more likely to have medical (e.g., 
hepatitis C, tuberculosis) and psychiatric (e.g., depres-
sion, anxiety) comorbidity, neurocognitive impairment 
[3], and increased risk for drug overdose [4], resulting in 
increased utilization of services, morbidity, and mortality 
[5–7]. Further, this population tends to cycle in and out 
of treatment, resulting in suboptimal health outcomes 
[8, 9]. PLWH who have a SUD tend to receive inadequate 
medical care [10] which is in part a byproduct of tradi-
tional HIV care and substance use services being deliv-
ered separately [11].
The Institute of Medicine has recommended integrated 
care between substance use disorder (SUD) treatment 
and primary care since 2006 [12, 13]; however, there 
remains a dearth of evidence in regards to the optimal 
method of service integration. Both HIV-infection and 
SUDs are chronic and treatable diseases requiring con-
tinued care [13]. With higher rates of SUDs among HIV-
infected populations [2], early identification of SUDs and 
referral to treatment is vital to effective clinical manage-
ment and prevention of HIV transmission. An interdis-
ciplinary, comprehensive, team-based coordinated care 
approach has been identified as the ideal treatment for 
PLWH who have a SUD [13]. Benefits of service inte-
gration have been noted at the patient-, provider-, and 
societal-levels, including decreased healthcare costs and 
improved treatment outcomes [14–16]. Ideal treatment 
includes an interdisciplinary team-based approach which 
can improve tracking and monitoring of patients, and 
coordination of comprehensive treatment plans, which 
may prevent treatment drop-out or expedite patient re-
engagement in care [16].
Many structural and systemic barriers impede the inte-
gration of treatment for HIV and SUDs. Start-up costs 
and limited building space are frequent deterrents of 
such integration. Consequently, patients with comorbid 
diagnoses tend to be referred to multiple providers at off-
site clinics and are often lost in the referral process. Fur-
ther, effective integration and quality treatment require 
additional staff and provider training in both HIV disease 
and substance use treatment [17]. Montague et  al. [18] 
identified several gaps in care among 119 HIV treatment 
providers and 159 SUD treatment providers. Results 
demonstrated that providers need cross-training to 
increase knowledge of risks associated with these comor-
bid conditions and require training in effective assess-
ment and identification for both diseases. Additional 
training needs included education about available refer-
ral sources for dual treatment and the need to define the 
role of SUD treatment providers in supporting HIV care 
[18]. Co-management of HIV and SUDs hinges on effec-
tive communication between a team of interdisciplinary 
providers. Current infrastructure frequently limits timely 
information transfer, resulting in deficits in communica-
tion. Further, cultural and language differences within 
the independent organizational structures and provider-
related stigma are important barriers to integrating HIV 
and SUD treatment [19]. There exists an urgent need 
for the healthcare infrastructure to adequately address 
the needs of dually diagnosed patients in a cost-effective 
and easily implemented manner. Information technology 
solutions designed for providers may address many of 
these barriers to dual care.
Rudin and Bates [20] identified four areas within a care 
coordination framework that would likely benefit from 
information technology solutions: (1) the ability to iden-
tify a patient’s care team both within and across settings 
and disciplines (including primary care providers, spe-
cialists, social worker, case manager, substance use coun-
selor), (2) the ability to collaborate with the care team in 
a quick and efficient manner, (3) the ability to collaborate 
through the sharing and formulation of care plans, and 
(4) the ability to monitor and track task responsibilities 
[20]. However, electronic health record (EHR) systems 
still lag in several areas including: information exchange 
across settings; development, storing, and sharing of care 
plans; tracking of referrals; and improved team-based 
communication [21].
A preliminary study conducted by the investigative 
team highlighted HIV and addiction treatment provider 
perspectives in regards to care coordination barriers and 
strategies to improve coordination [22]. In-depth quali-
tative interviews revealed concerns that EHRs, as they 
are currently designed, may result in poorer comprehen-
sive care for PLWH who have a SUD as a result of stigma 
related to the documentation of both HIV disease and 
substance use. Providers expressed a desire for develop-
ment of an integrated, secure technology platform spe-
cifically designed for HIV and addiction providers as a 
solution to improved communication and care coordina-
tion across disciplines. Recommended features included 
an instant messaging system, identification of the 
patient’s care team and contact information, real-time 
notifications, HIV and SUD training resources, and com-
munity resources. Providers conveyed interest in a range 
of potential delivery modalities including a web-based 
platform and mobile platforms accessed through tablet 
or mobile phone devices. When asked explicitly what 
platform they would prefer, a majority of providers pre-
ferred a tablet- or phone-based mobile platform, due to 
the perceived benefits of increased mobility provided by 
these devices. Additional perceived benefits included the 
capability to interact with patients with the technology 
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interface on a tablet device during appointments and 
potential for features to allow real-time notifications and 
easy access to data (e.g., have alarms for notification if a 
high-risk patient missed appointments or is admitted 
into the emergency department). Some providers noted, 
however, that they would most value a mobile platform 
if it could either be co-located (i.e., stored on the same 
workstation) or fully integrated (i.e., embed within) the 
EHR in order to minimize duplication of data entry, high-
lighting the need for a tool that can be flexibly delivered 
to meet provider preferences.
Mobile health technology offers a unique potential 
platform for rapid communication among providers 
and tracking of patient service utilization and treatment 
approaches. Additionally, it has the potential to improve 
the team-based approach consistent with the collabora-
tive care model, while promoting more effective care 
in hard-to-retain populations that place a significant 
burden on the healthcare system, such as PLWH who 
have a SUD. Currently, there are over 200 HIV-related 
mobile health applications marketed for PLWH on either 
android or apple platforms. A 2013 review of mobile 
applications found that only 55 apps promoted HIV pre-
vention and care services, and the majority of these apps 
focused on providing disease-specific educational infor-
mation only [23]. No mobile applications were identified 
for treatment providers. Mobile applications are unique 
among devices and tools used in clinical practice in that 
there is currently no mechanism for regulating them or 
ensuring they are efficacious or beneficial. A theory-
driven and empirically tested technology platform for 
providers that over the long-term be flexibly delivered as 
either a stand-alone product or integrated with the EHR 
has the potential to improve coordination and treatment 
management of dually diagnosed patients.
For the purposes of this study, care coordination is 
defined as “the deliberate organization of patient care 
activities between two or more treatment settings [HIV 
clinic, SUD clinic] involved in a patient’s care to facilitate 
the appropriate delivery of health care services; organ-
izing care involves the marshalling of personnel and 
other resources needed to carry out all required patient 
care activities and is often managed by the exchange of 
information among participants responsible for differ-
ent aspects of care” (p. 2) [24]. Van Houdt et al. [24, 25] 
developed a theoretical framework of care coordina-
tion which encompasses organizational-, provider-, and 
patient-level characteristics (see Fig. 1). This framework 
will guide the development of a technology-assisted care 
coordination intervention (CCI) for HIV and substance 
use treatment providers. Consistent with the Care Coor-
dination framework, the CCI seeks to improve relational 
coordination components through modification of the 
inter-organizational mechanisms of structure, knowledge 
and information technology, administrative operational 
processes, and cultural factors. A wealth of literature has 
Fig. 1 Care coordination framework adapted from Van Houdt et al. [25]
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demonstrated that didactic training-alone is insufficient 
to produce optimal change [26, 27]. Thus, we will use an 
evidence-based comprehensive training approach to pro-
mote adoption of the CCI that addresses both organiza-
tional and individual provider level factors [28–30].
Present study
This study uses mixed methods to optimize care coor-
dination of patients diagnosed with HIV and substance 
use issues using an organizational-level intervention that 
combines an evidence-based training approach with use 
of mobile technology. The proposed project consists of 
three phases. In Phase 1, we will use qualitative data to 
guide the development of the CCI and training approach. 
Phase 2 will consist of a series of functionality tests of 
the tablet-based mobile application prototype using fake 
patient data with HIV and SUD treatment providers, and 
a review of the intervention with a stakeholder panel of 
clinic leadership. Data regarding feasibility, acceptability, 
and barriers that would limit effectiveness of the inter-
vention will guide modifications to finalize the software 
and the training protocol. In Phase 3, we will conduct a 
pre-, post-test trial of the CCI to examine its effects on 
the amount and quality of interagency communication, 
perception of interagency professional relationships, 
and retention of patients in dual care. Preliminary data 
regarding intervention costs and sustainability potential 
will be collected. Table 1 depicts the timing of key proto-
col elements for the Phase 3 pilot trial including provider 
enrollment, provider training, and assessments.
The primary goal of this protocol is to develop and test 
a CCI among HIV and SUD treatment providers. We 
hypothesize that the combination of training and mobile 
health tools specifically created for HIV and SUD care 
coordination will (a) increase patient retention in dual 
care, (b) increase the amount of communication between 
HIV and addiction treatment providers, and (c) improve 




Two organizations in the Northeast region of the United 
States, an academic affiliated HIV clinic and a non-profit 
SUD treatment facility, will serve as the recruitment 
and implementation sites for the CCI. The HIV clinic is 
funded by the Ryan White program and provides com-
prehensive care for over 1600 HIV-infected patients. The 
clinic also has a pre-exposure prophylaxis (PrEP) pro-
gram which offers a single, daily pill to patients at higher 
risk for HIV exposure to prevent the person from being 
infected with HIV. The collaborating SUD treatment pro-
gram is a non-profit organization that provides substance 
use treatment, recovery, and prevention services to about 
950 new patients annually across four clinics. These 
services include general outpatient (drug free) or inten-
sive outpatient counseling for alcohol and drug-related 
problems.
Key stakeholders (n = 8 in Phase 1: stakeholder inter-
views) and frontline HIV and SUD treatment providers 
(n  =  8 in Phase 2: functionality testing; and n  =  60 in 
Phase 3: Pilot Trial) will be recruited from the HIV and 
SUD clinics. Upper management in each organization 
will inform providers that participation in the study is 
available and they may volunteer to participate; providers 
will be explicitly informed that participation is voluntary 
and will not affect their employment. Once a potentially 
eligible provider has been identified, the RA will contact 
the provider, introduce the study, and assess eligibil-
ity. For inclusion, key stakeholders must: (a) be at least 
18 years of age, (b) have a major administrative or leader-
ship role (i.e., President/CEO, Clinic Director, Executive 
Table 1 Timing of provider enrollment, training, and assessment activities
Timepoint Enrollment Training Post-didactic training




Didactic sessions #1–3 X
Interagency communication manual X
Internal change champions X X X X
External leadership coaching X X X X
Assessments
Provider-level outcomes X X X X X
Organizational-level outcomes X X X X
Patient-level outcomes X X
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Leadership) in an HIV or SUD treatment center, (c) have 
been employed in their current leadership position for 
at least 6  months, and (d) able and willing to provide 
informed consent. Treatment providers must: (a) be at 
least 18 years of age, (b) provide either HIV care or SUD 
treatment [e.g., physicians, residents, psychologists, mid-
level providers], (c) have been employed at a participating 
recruitment site for at least 6 months, (d) have no plans 
for a leave of absence over the next 2 years and (e) will-
ing and able to provide informed consent. We will recruit 
an even number of stakeholders and providers from HIV 
and SUD treatment centers. We recognize that staff turn-
over may occur throughout the study and especially dur-
ing Phase 3 (6-month intervention phase). Providers who 
leave employment during the trial period will be asked to 
return the tablet device to the study and will be removed 
from participating in the CCI for the remainder of the 
study. Participants in Phase 1 (stakeholder interviews) 
will receive $75, and participants in Phase 2 (functional-
ity testing) will be paid $50. In Phase 3 (pilot trial), par-
ticipants will be paid $50 for completion of the baseline 
interview and $40, $45, and $50, respectively, for comple-
tion of the 1-, 3- and 6-month follow-ups. Participants 
completing exit interviews will receive an additional $50.
Procedures
Phase 1: qualitative methods to inform intervention 
development
Individual interviews with 8 key stakeholders and clinic 
audits will be used to inform development of the CCI. 
All qualitative interviews will follow a semi-structured 
agenda covering the following topics: (a) interagency pro-
cesses that facilitate or impede interagency collaboration; 
(b) organizational resources available to support intera-
gency collaboration; (c) professional knowledge domains 
and boundaries (i.e., substance use providers knowledge 
of HIV care and vice versa); (d) expectations in regards 
to authority to coordinate treatment; (e) issues of patient 
confidentiality in regards to coordination of HIV and 
SUD care. Interviews will last approximately 60 min, and 
participants will receive $75. We will regularly assess 
data saturation on key topics and may conduct a higher 
number of interviews if more information is required. 
In addition, the CCI will be informed by 29 individual 
interviews with HIV and SUD treatment providers that 
were conducted as part of another NIDA funded study 
(K23DA039037). The goal of this phase is to gather 
organizational-level data to evaluate potential barriers 
and facilitators to collaboration within each clinic setting.
Audit of  referral and  communication process To aug-
ment the stakeholder interviews, audits within each clinic 
will be conducted to assess existing referral and commu-
nication procedures. Data to be extracted include number 
of relevant referrals by provider type, number of patients 
followed post-referral, and language used in referrals and 
consult letters. These data will inform the interagency 
communication protocol and language for the CCI.
Coding and  analysis Qualitative data will be analyzed 
using a thematic framework method [31]. This method 
will allow the investigative team to develop themes from 
both the research questions and the narratives of the 
research participants [32]. A preliminary coding structure 
will be derived deductively from the interview script, with 
specific subtype coding applied inductively as themes 
and repetitions emerge from the data. Data analysis will 
be iterative using standard analysis techniques, including 
open coding, axial coding, marginal remarks, and memo-
writing [33]. Preliminary research questions include: (1) 
what are the gaps in existing referral and communication 
processes; (2) how do providers exchange patient infor-
mation; (3) how do providers perceive the need for care 
coordination; and (4) what is the level of cross-training 
and available resources.
Phase 2: intervention and manual development & refinement
Based on data triangulated from Phase 1 and evalua-
tion of the literature, we will develop the CCI prototype 
and refine the training and intervention protocols. The 
development of the CCI will involve a series of meet-
ings among the investigators and the software develop-
ment team to review the core elements and features of 
the mobile application. The goal of these meetings will 
be to match the intervention content and structure to 
the needs and preferences identified through formative 
research.
Intervention The CCI will consist of a mobile application 
developed for treatment providers, an interagency commu-
nication protocol, and a training protocol. The mobile appli-
cation will be developed on a secure portable platform that 
providers will access through study-provided tablet devices. 
The CCI dashboard will be user friendly and easily naviga-
ble. The application will feature a secure messaging center 
for providers to directly communicate. Other application 
features will include: (a) resources for methods of iden-
tifying patients in need of dual care, (b) a system to refer 
patients to treatment, (c) ability to track patients’ access and 
utilization of services, (d) real-time patient care notifica-
tions, (e) identification of a patient’s care team, and (f) up-
to-date lists of resources and evidence-based recommenda-
tions for treatment options. The CCI will provide a secure 
platform that will enable the transfer of patient health infor-
mation between providers, yet will not be linked in the same 
electronic health record system, adding an additional level 
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of privacy for patients who do not wish for non-HIV/SUD 
providers to have access to this sensitive data. These features 
of the CCI prototype are based on preliminary work [22]; 
however, the final app will reflect data gathered from the 
Phases 1 and 2 of the study.
Refinement of the mobile application and training materi‑
als Once the prototype CCI and training materials have 
been developed, these materials will be refined through 
an iterative process whereby we will test the functionality 
of the CCI with 6–8 providers. During these individual 
interviews, we will demonstrate the CCI features and 
solicit feedback on the training procedures and the inter-
agency communication protocol. These data will inform 
modifications to the CCI. Once modifications have been 
completed, the investigative team will have a 2-h (in-per-
son/teleconference/Skype) meeting with the 8 stakehold-
ers who participated in Phase 1 to review modifications 
and finalize the CCI.
Phase 3: provider training and intervention testing
Phase 3 will test the organizational intervention. We 
recognize use of the mobile application alone is likely 
to yield minimal improvements in care coordination. 
Consequently, the proposed intervention augments the 
mobile application with training of providers and on-
going support for training needs.
Training procedures Although the primary aim of the 
proposed study is intervention development, we are 
mindful of the need to have an evidence-based replicable 
training protocol to facilitate widespread implementa-
tion. We use the Service to Science Laboratory (SSL) staff 
training model, which was specifically developed by the 
SAMHSA-funded Addiction Technology Transfer Cent-
ers (ATTCs) to increase support for intervention adoption 
at both the individual-level and organizational-level. The 
SSL model contains three key elements: upfront didactic 
training, ongoing performance feedback, and ongoing 
coaching from an external leadership coach who works 
with Internal Change Champions within each organiza-
tion [34].
The upfront didactic training will be led by a member 
of the New England ATTC staff and will consist of three 
training sessions (see Table 2 for an overview of topics). 
Participants will complete a 20-item baseline knowledge 
assessment prior to Training Session #1. All training ses-
sions will be audio-recorded and participants who are 
unable to attend will be required to listen to the audio 
recording and attend a brief make-up training session. 
Upon completion of Training Session #3, each treatment 
provider will be required to complete a 20-item post-
training knowledge assessment and to demonstrate ade-
quate knowledge, defined as accurate answers to 16 (80%) 
of the items. Each provider will also complete a role play 
with the ATTC trainer using a standardized patient case. 
During the role play, the provider will be required to 
demonstrate competence in the following six areas: (a) 
identifying resources to detect patients in need of dual 
care, (b) using the referral system (including ability to 
Table 2 Expected features and benefits of the care coordination intervention (CCI) based on preliminary qualitative work
Training procedures
Interagency communication protocol Include a manual for the mobile app and outline communication procedures and 
language
Didactic Session 1 (conduct separately at each clinic) Provide study details, solicit buy-in and commitment to change, cross-training in HIV/
SU issues
Didactic Session 2 (conduct concurrently at neutral location) Train in CCI and study procedures, introduce participants from each clinic
Didactic Session 3 (conduct separately at each clinic) Hands-on practice with the mobile application using fake patient data, pass a CCI 
competency test





Patient linkage to dual care Care coordination Work flow Dual care resources
Portable platform Identification of patients in 
need
Identification of care team Direct referrals from provid-
ers
Patient educational resources
Secure messaging center Easy referral system Easily develop dual care 
plans




Notification of message 
receipt
Track patient’s service 
usage/appointment 
attendance
Communicate with care 
team via SMS procedures
Decrease time spent on 
coordinating care
Available community 
resources and admission 
criteria
Remote access to system Link to HIV/PrEP/SU services Track and manage dual care Decision trees for referrals Identify provider availability
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both make a referral and accept a referral request), (c) 
tracking of patients’ access and utilization of services, (d) 
reading real-time patient care notifications, (e) identify-
ing a patient’s care team, and (f ) reviewing up-to-date 
lists of resources and evidence-based recommendations 
for treatment options. Providers who do not demonstrate 
competence will receive immediate corrective feedback 
and up to two additional role plays will be conducted 
until competence is shown. Only those providers who 
exhibit competence in all six areas will proceed to the 
next phase of training.
After completion of the 3-session didactic training 
series, we will enable the mobile application, assign each 
provider a tablet device, and initiate the 6-month open 
trial. At this point, the SSL training model will shift from 
a focus on didactics to ongoing interpersonal support. 
The SSL relies heavily on supportive interpersonal per-
sonal strategies through the use of an external leadership 
coach and Internal Change Champions, who continually 
encourage collaborative problem solving throughout the 
organization. The eight key stakeholders will be respon-
sible for either serving as Internal Change Champions or 
selecting alternates. The external leadership coach will 
have monthly coaching calls with the Internal Change 
Champions focused on tracking implementation pro-
gress and engaging in problem solving to address barri-
ers to sustained use of the mobile application. In turn, 
the Internal Change Champions will be responsible for 
providing ongoing supervision and support to frontline 
treatment providers. Consistent with the recommen-
dations of Montague et al. [18], who noted the need for 
cross-training among HIV and substance use providers, 
the SSL will include cross-training via explicit didactic 
instruction and ongoing coaching in an effort to increase 
understanding of each provider’s role and disease specific 
processes.
Measures The framework identified in Fig.  1 has 
informed the battery of measures. Assessments will focus 
on organizational-, provider-, and patient-level domains 
(see Table  3). Primary outcomes will be feasibility and 
acceptability of the CCI and assessment procedures to be 
used in a larger trial [35]. Organizational outcomes will 
include pre- and post-intervention assessments of each 
clinic to gather data on organizational structure and pro-
cedures for care coordination. Provider outcomes will 
include feedback on the intervention component in Phase 
1 and 2 of the trial; satisfaction of care coordination, fre-
quency and quality of interagency communications, and 
interagency professional relationships; and potential 
moderators (e.g., stigma, perceived coercion). Patient out-
comes will include demographics, viral load, and reten-
tion in dual care. Quantitative measures will be collected 
via web-based surveys from clinic leadership (n = 8) and 
providers (n = 60) at baseline and 1-, 3-, and 6-months 
post implementation of the CCI (Phase 3).
Provider‑level descriptives The following basic demo-
graphic and clinical experience data will be collected 
from providers enrolled in the study at baseline: age, gen-
der, race, ethnicity, educational attainment, employment 
status, position title, number of years in practice, level 
of experience treating patients with HIV and substance 
use, knowledge of HIV and substance use treatment, and 
prior training experience. Providers will also complete 
measures indicating their willingness to participate in the 
study and their perceptions of stigma related to dual care. 
The Coercion Assessment Scale (CAS) [36, 37] is an 8-item 
measure of voluntariness to participate in research. The 
Provider Perception Inventory [38] is a 39-item scale that 
measures health service providers’ stigma in regards to 
HIV, substance use, and MSM behavior, which will be 
used to measure provider-related stigma.
Provider acceptability and usability of the CCI We will 
measure providers’ perceived acceptability of and satis-
faction with the CCI, as well as their perceptions of the 
intervention. Provider acceptability data will be gathered 
primarily through qualitative exit interviews at the 6- 
month follow-up. Providers will also be asked to complete 
a program satisfaction survey which will assess level of 
satisfaction for each component of the CCI. Perceptions 
of the intervention will be measured via the Perceived 
Attributes Scale, a 27-item, customizable scale that meas-
ures five aspects of an intervention or innovation (i.e., 
Relative Advantage, Compatibility, Complexity, Trial-
ability, Observability) that have been shown to influence 
adoption.
Interagency collaboration and  communication CCI 
usage will be measured via the mobile application dash-
board throughout the study. The Levels of Collaboration 
Scale [39] will be adapted for the purposes of this study 
and will measure progress over the five levels of collabo-
ration and their characteristics (networking, cooperation, 
coordination, coalition, collaboration). The Wilder Col-
laboration Factors Inventory [40] is a 40-item measure 
that assesses strengths and weaknesses within organiza-
tions shown to be important for successful collaborations. 
Factors include: collaboration history, organizational cli-
mate, mutual respect, definition of roles, adaptability, and 
shared goal setting.
Relational coordination A Relational Coordination Scale 
will be developed by the investigative team as there are no 
available measures assessing these constructs. This measure 
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will include items assessing the following constructs: defini-
tion and awareness of provider roles in the co-management 
of HIV and substance use; quality of relationships between 
clinic providers (e.g., mutual respect, collaboration); 
exchange of information (e.g., transfer of information, ideas, 
and opinions); and setting and sharing of common goals.
Organizational‑level We will evaluate organizational-
level descriptive characteristics as well as putative organi-
zational mediators of CCI usage. Descriptive organiza-
tional data from participating clinics will be collected 
during both pre- and post-implementation site visits and 
include (a) number of patients at each clinic diagnosed 
with comorbid HIV/SUD enrolled in care; (b) num-
ber of patients receiving care at the SU clinic who are 
referred to testing and number tested for HIV, number 
of patients referred to HIV care or PrEP; (c) number of 
patients receiving care at the HIV clinic who are assessed 
for a substance use problem and number referred for sub-
stance use treatment; (d) number of patients receiving 
co-management care of HIV and substance use. At the 
6-month post-implementation assessment, will measure 
also measure CCI Reach by tracking the percentage of 
eligible providers who participated and reasons providers 
chose not to participate. We will measure Organizational 
Readiness to Implement Change and Implementation 
Climate as putative mediators of CCI adoption at base-
line, 1, 3, and 6  months. The Organizational Readiness 
for Implementing Change (ORIC) [41] questionnaire is a 
12-item measure on a five-point scale, 1 (“disagree”) to 5 
(“agree”). This scale will be administered to providers and 
key stakeholders to determine the extent to which there 
is a shared perception of organizational readiness for the 
CCI. The Implementation Climate Scale [42] will measure 
the degree to which there is a strategic organizational cli-
mate supportive of intervention implementation. This is a 
38-item questionnaire that is scored on a five-point scale, 
0 (“not at all”) to 4 (“very great extent”).
Table 3 Outcome variables and assessment points
BL baseline, I implementation, T training, MDE Data extracted through the mobile app dashboard, CDE data extracted through clinic medical records, EXPL exploratory, 
QUANT quantitative, HYP hypothesis
* Primary Outcome Variable
Quantitative measures BL Post-T 1-, 3- mos 6 mos Analysis
Provider-level outcomes
 Provider descriptive information
  Provider demographics X Descriptive
  Training in HIV and SU issues X X X Descriptive
  HIV/SU treatment experience X X X Descriptive
  Knowledge related to SU/HIV X X X Descriptive
  Coercion assessment scale X X X Exploratory: Moderator
  Provider perception inventory X X X Exploratory: Moderator
 Provider acceptability and usability of the CCI and training protocol
  Satisfaction with training X Acceptability
  CCI program satisfaction X Acceptability
  Perceived attributes scale X X X Exploratory: Mediator
 Interagency collaboration and communication
  Levels of collaboration scale* X X X Quant: Hyp 2
  Frequency/quantity of communication* MDE MDE MDE Quant: Hyp 2
  Wilder collaboration factors inventory X X Exploratory: Moderator
 Relational coordination
  Relational coordination scale* X X X Quant: Hyp 3
Organizational-level outcomes
 Organizational descriptives X X Descriptive
 Organization readiness X X X Exploratory: Mediator
 Implementation climate scale X X X Exploratory: Mediator
Patient-level outcomes
 Descriptive information
  Demographics MDE Descriptive
  Viral load MDE MDE Descriptive
  Dual care treatment retention C/MDE C/MDE Quant: Hyp1
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Preliminary assessment of  implementation con‑
text Although this study is an intervention development 
study, the mixed-methods design will allow us to gather 
preliminary data in regards to implementation context 
and information transfer that inform future multisite tri-
als. We will conduct individual qualitative interviews with 
4–5 key stakeholders at 6 months following implementa-
tion of the CCI. These interviews will gather data regard-
ing perceptions of providers and leadership concerning 
barriers and facilitators to CCI adoption, tools needed 
to deliver the intervention consistently, resources needed 
to maintain the CCI long-term, and adaptations needed 
to integrate the CCI into regular practice. Qualitative 
data from exit interviews will be triangulated to examine 
themes related to barriers and facilitators of CCI adop-
tion, stakeholder and organizational satisfaction with the 
CCI, and acceptability of the CCI. Additionally, we will 
measure the following costs associated with CCI imple-
mentation: training hours (study staff and provider time) 
and equipment and other resources costs.
Patient outcomes Patient information will be de-iden-
tified for the study, and the research team will not have 
access to any private health information. Patient outcomes 
will be extracted through the mobile dashboard and medi-
cal chart review. No patients will be contacted for the pur-
poses of this intervention development study; however, we 
recognize the importance of assessing patient outcomes 
in future trials. De-identified patient demographic data 
including age, gender, sexual orientation, race, ethnicity, 
educational attainment, employment status, HIV status 
and length of time since diagnosis, viral load, and type 
of substance use problem will be extracted through the 
dashboard on all patients entered into the system by pro-
viders. Dual care retention data will be extracted through 
the dashboard in regards to (a) number of appointments 
attended at the HIV and substance use clinics, (b) number 
of appointments missed, and (c) number of patients who 
were not retained in care.
Data analysis plan
Preliminary analyses
Considering this is a pilot study, analyses will have the 
goal of establishing feasibility and estimation of effect 
sizes, with modest expectations for rejection of null 
hypotheses. This is especially true regarding analyses 
containing higher order effects and multiple predictors. 
Formal quantitative data analyses will be conducted 
only on those subjects recruited during Phase 3 of the 
project. Preliminary analyses will include data cleaning 
and examination of key demographic and baseline vari-
able differences between the HIV providers and the sub-
stance use providers. These analyses will be exploratory 
in nature and used to describe the providers in each 
clinic. We will summarize variables at both the organi-
zational and provider unit of analysis. Other preliminary 
analyses will include examinations of patterns of missing 
data, research dropout rates, distributional properties of 
dependent and other measures, and correlations among 
outcome measures.
Hypotheses testing
Given the developmental nature of this study, our pri-
mary objective is to establish feasibility and acceptabil-
ity of the CCI and assessment procedures. The following 
deliverables will result from this study: evidence-based 
training model adapted to HIV and substance use pro-
viders, mobile application tool for providers targeting 
care coordination, interagency communication protocol, 
and a training strategy for the CCI. This study will yield 
necessary data regarding the acceptability and feasibil-
ity of the approach to be implemented in a future larger 
scale multisite trial [35]. We are well aware of the dan-
gers of relying exclusively on small-scale pilot studies to 
gauge the promise of a novel intervention [43]. Thus, we 
primarily will be hoping to find a pattern of results that 
is supportive of the CCI rather than rigorously testing 
hypotheses to determine a stable effect size. Hypotheses 
include: (1) Compared to baseline, providers will demon-
strate increased dual care treatment retention as meas-
ured by data in the EHR; (2) Compared to baseline, HIV 
providers will report increased frequency and quantity of 
communication with substance use providers, and sub-
stance use providers will report increased frequency and 
quantity of communication with HIV providers; and (3) 
Providers will report improvements in relational coordi-
nation as measured by increased scores on the Relational 
Coordination scale between baseline and follow-up 
assessment. Group means on continuous variables typi-
cally begin to stabilize around 15 participants per group. 
For dichotomous variables, somewhat larger sample size 
is needed to provide reasonably stable odds ratios for 
effect size estimates. Therefore, the proposed sample 
size of 30 participants per group, even after attrition, will 
allow us to evaluate the potential of the CCI intervention 
to improve care coordination while remaining within the 
budgetary parameters for a preliminary trial.
Tests of the effects of the intervention on the primary 
outcome variables (identified in Table 1 at BL, 1-, 3-, and 
6-months) will be conducted using repeated measures 
ANOVAS on change scores. We will examine each organ-
ization separately and then develop a composite score 
to examine change across time. We will use repeated 
measures mixed model analysis of variance (ANOVA) 
to assess main effects and between-group effects on the 
primary and secondary dependent variables. We will test 
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for the normality of the distributions, homogeneity of 
covariance matrices, and sphericity. If violations of the 
sphericity assumptions are found, we will use the Green-
house Geyser Epsilon to adjust the probability of F [44]. 
Omnibus F testing will be followed by univariate tests to 
examine if primary outcome variables differ by condi-
tion (HIV vs SU provider). Analyses will be conducted 
using SAS Proc GLM, which allows for maximum use of 
observations across time even when some data are miss-
ing. To determine whether there was an effect of group, 
time, or a group × time interaction on the primary out-
come variables specified a priori: (1) collaboration, and 
(2) frequency of interagency communication, and on the 
secondary outcome variable specified a priori: (1) intera-
gency relationships as measured by relational coordina-
tion, we will conduct 4 repeated measures ANOVAs with 
2 levels of condition (HIV provider and SU provider) 
and 3 levels of time (baseline, 3-mos FU, 6-mos FU). If 
the null hypothesis is rejected in omnibus testing, we 
will conduct further univariate tests of hypotheses for 
between-groups and main effects and calculate effect 
sizes for the effects observed across time (Eta squared). 
In addition, for each primary outcome variable at each 
follow up point, effect sizes and 95% confidence intervals 
will be computed.
Missing data
Although our follow-up rates in similar studies have 
exceeded 90%, some data will inevitably be missing. Rea-
son for study dropout will be collected whenever possi-
ble and will be summarized. We will explore patterns of 
missing data to determine possible mechanisms of miss-
ingness and will apply multiple imputation techniques. 
We will also run a sensitivity analysis in which we will 
impute the outcome data for those with whom we have 
lost contact, using various missing data mechanisms that 
describe possible relationships between the study out-
come and missingness. If the results of these sensitivity 
analyses are similar with and without the missing data, 
our confidence in the findings will increase.
Discussion
Drug use remains a significant problem within the HIV 
pandemic. PLWH who have a SUD exhibit the high-
est rates of ART nonadherence among those people 
infected with HIV, contributing to poor treatment out-
comes, increased morbidity and mortality, and HIV 
transmission [6, 7]. Existing treatment structures pre-
sent significant challenges to adequately treating HIV 
disease and substance use disorders concurrently using 
a team-based approach among providers. This protocol 
seeks to improve clinical practice and treatment science 
by developing a combined evidence-based training and 
mobile application intervention for HIV and substance 
use disorder treatment providers. The application will be 
flexibly developed to enable potential future integration 
with the electronic health record in order to flexibly meet 
the needs of individual providers. This care coordination 
intervention will address critical inter-organizational and 
provider factors aimed at improving dual care and test a 
preliminary implementation approach.
While this study will advance our knowledge regarding 
approaches to care coordination among high-risk popu-
lations, a few important limitations should be acknowl-
edged. First, this study design does not include a control 
condition due to the developmental nature of the proto-
col and to increase trial feasibility within the context of 
limited budgetary resources. Second, the mobile applica-
tion will not be integrated with electronic health records 
in this initial phase, though the application will be devel-
oped to allow for integration in future versions. We chose 
to use a separate mobile platform that only HIV and 
SU providers will be able to access during this develop-
ment phase for several important reasons: (a) concerns 
that the stigmatizing nature of HIV and SUD diagno-
ses might lead to inaccurate documentation in the EHR; 
(b) concerns about participant confidentiality since all 
healthcare providers have access to EHR records, and (c) 
concerns about the lack of EHR integration at our partic-
ipating community partners, which do not currently uti-
lize the same platform. The goal of this study phase is to 
develop the ideal features of the mobile application and 
obtain preliminary data on its acceptability, feasibility, 
and usability. Because EHRs and mobile technology are 
both rapidly evolving, we test the application as a stand-
alone product in order to maximize long-term flexibility 
in terms of features and the potential for integration with 
different EHR systems. If the mobile application appears 
to be effective in promoting increased coordination, then 
the next logical question that we will evaluate in future 
research is whether the application is most effective 
when delivered as a stand-alone application, co-located 
with the EHR, or fully integrated into the EHR.
To our knowledge, no research to date has focused on 
establishing the acceptability, feasibility, and usability of 
mobile applications to improve care coordination with 
healthcare providers as the target market. Delivered over 
a smartphone or tablet device, such portable applications 
could allow for real-time patient tracking of services and 
on-demand access to content or services to enhance care 
coordination. This technology, combined with evidence-
based cross-training in HIV and substance use, has the 
potential to overcome cracks in a fragmented healthcare 
system and increase clinic efficiency, work flow, and com-
munication among interdisciplinary providers and pro-
viders of different levels. This study will produce a care 
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coordination intervention, using combined training and 
mobile technology tools for providers and an organi-
zational integration care model that can be portable to 
other clinics for dissemination.
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